Source comparison
IGF-1 Elevation vs Testosterone Replacement — Mechanistic Differences
Testosterone replacement therapy (TRT) addresses one axis of andropause: declining androgen receptor activation in muscle, bone, and central nervous system tissue. But TRT doesn't restore GH pulsatility or IGF-1 production. Those systems degrade independently.
This comparison does not assign a generated winner or score.
- Testosterone replacement therapy (TRT) addresses one axis of andropause: declining androgen receptor activation in muscle, bone, and central nervous system tissue. But TRT doesn't restore GH pulsatility or IGF-1 production. Those systems degrade independently. IGF-1 mediates most of growth hormone's anabolic effects: it activates mTOR (mechanistic target of rapamycin) pathways in skeletal muscle, driving protein synthesis and myonuclear accretion. It stimulates osteoblast activity in bone tissue, increasing bone mineral density. And it enhances lipolysis in adipose tissue by upregulating hormone-sensitive lipase, the enzyme that cleaves triglycerides into free fatty acids for oxidation.
- MK-677 andropause research mechanism operates upstream of these processes. By restoring GH secretion, it elevates IGF-1 without suppressing the hypothalamic-pituitary-gonadal axis the way exogenous androgens do. TRT shuts down endogenous testosterone production because exogenous testosterone provides negative feedback to the pituitary, suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). MK-677 doesn't interfere with this axis at all. It works on the somatotropic axis exclusively. That's why some clinicians pair MK-677 with TRT in aging males: one restores androgen signaling, the other restores anabolic GH-IGF-1 signaling.
- Clinical evidence supports additive effects. A 2022 observational study in Aging Male tracked 83 men aged 50–65 on stable TRT (100–200mg testosterone cypionate weekly) who added 20mg daily MK-677 for six months. Body composition analysis showed 2.1 kg mean increase in fat-free mass and 1.4 kg mean reduction in trunk fat mass compared to TRT-only controls. Fasting glucose rose modestly (mean +6 mg/dL) but remained within normal range, and HbA1c did not change significantly. Suggesting MK-677's transient impact on glucose tolerance is clinically manageable in non-diabetic populations.